Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript May 9, 2024 Sangamo Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Sangamo Therapeutics First Quarter 2024 Teleconference Call. At this time, all […]
Sangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?